secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K/A
Filed at:   2023-06-02T23:59:59+00:00
Accession:  0001104659-23-067589
Event type: other_material
Sentiment:  negative
Materiality: 0.40
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance files audited financials for Proleukin acquisition; FY2022 revenue $21.6M, net loss $10.2M
--------------------------------------------------------------------------------

- Proleukin revenue fell to $21.6M in FY2022 from $40.1M in FY2021; net loss of $10.2M vs profit $7.4M.
- Impairment of intangible assets of $2.7M recorded in FY2022.
- Auditors include going concern material uncertainty due to disposal to Iovance.
- Unaudited pro forma financials for Q1 2023 and FY2022 filed as Exhibit 99.3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465923067589/0001104659-23-067589-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465923067589/tm2317343d1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-067589

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer